C12orf43 Antibody

Cancer Biology

The antibody has been pivotal in elucidating C12orf43’s role in breast cancer chemoresistance:

• Mechanism: C12orf43 interacts with NAT10, an enzyme responsible for N4-acetylcytidine (ac4C) RNA modification. This interaction stabilizes BMI1 mRNA, leading to P53 ubiquitination and degradation, thereby promoting tumor progression .

• Experimental Techniques:

  • Co-immunoprecipitation (Co-IP): Validates C12orf43/NAT10 complex formation .

  • RIP-sequencing (RIP-seq): Identifies BMI1 as a downstream target of ac4C modification .

Cardiovascular Disease

While primarily studied in oncology, C12orf43 has been linked to coronary artery disease in genetic association studies . The antibody may aid in investigating its role in vascular pathologies.

Breast Cancer Therapy

• Quercetin Synergy: The antibody has been used to validate quercetin’s disruption of the C12orf43/NAT10 interaction, which reverses doxorubicin (ADM) resistance in breast cancer models .

• Diagnostic Utility: Elevated C12orf43 expression correlates with chemoresistance, positioning it as a potential biomarker for personalized therapy .

Limitations and Challenges

• Specificity: Cross-reactivity with orthologs (e.g., mouse: 69%, rat: 58%) requires careful validation in non-human studies .

• Clinical Translation: No approved therapeutic applications yet; preclinical data focus on mechanistic insights .

Comparative Analysis of C12orf43 Antibody Formats

Emerging Applications

• Epigenetic Modulation: Investigating C12orf43’s role in RNA ac4C modification beyond BMI1, such as targeting oncogenic mRNAs .

• Therapeutic Targeting: Developing small-molecule inhibitors or CRISPR-based tools to modulate C12orf43/NAT10 interactions .